TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03321760

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation Therapy (SABR)
Description: SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation Therapy (SABR)
Description: SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation Therapy (SABR)
Description: SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation Therapy (SABR)
Description: SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
Study: NCT06556641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR33 Injection
Description: Administered as once daily subcutaneous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR33 Injection
Description: Administered as once daily subcutaneous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR101 Injection
Description: Administered as once daily subcutaneous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as once daily subcutaneous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered as once daily subcutaneous dose
Study: NCT06633796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMADEO
Description: 304 / 5.000 The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy, functional occupational therapy and polyarticular mobilization of the fingers with a robotic arm (Amadeo). The sessions will be scheduled 2 times a week for 5 consecutive weeks.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy and occupational therapy for functional purposes. The sessions will be scheduled 2 times a week for 5 consecutive weeks.
Study: NCT06557538

Intervention type: DEVICE
Intervention: Automatic Ankle Brachial Pressure Index device assessment
Description: The automatic device assesses 3 limbs, providing automatic simultaneous ABPI measurement of systolic, diastolic and mean arterial blood pressure on to calculate the patient\&#39;s ABPI (Medi UK 2022).

Intervention type: DEVICE
Intervention: Manual Ankle Brachial Pressure Index assessment
Description: The manual device assesses 4 limbs, providing brachial, ankle and pedal systolic pressures. A simple calculation is then made by the clinician to determine the ratio of ankle and brachial systolic pressure (ABPI) (Day 2015).
Study: NCT05324722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic posterior capsular stretch
Description: pragmatic posterior stretch is used to increase the length of the posterior capsule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cross body stretch
Description: crossbody stretch performed by an individual
Study: NCT06355557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AI enabled ultrasound system for self-directed learning
Description: use of the AI enabled ultrasound system for self-directed learning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulator for self-directed learning
Description: use of the simulator for self-directed learning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional with human instructors
Description: Medical students who are randomised to this arm
Study: NCT06675669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflective thinking method
Description: It will be applied to students in the initiative group for 1 hour per week for 7 weeks.
Study: NCT06621277

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: Tailored counseling programs (Phase 2)
Description: Optimized care services and tailored counseling programs for young patients with GI tumors at the Heidelberg University Hospital (Phase 2)
Study: NCT05509751

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GAM, exercise, health education
Description: geriatric assessment, exercise and health education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online chair-based exercise combined with health education
Description: online chair-based exercise and health education for 12 weeks
Study: NCT05734495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor, tablet taken orally.
Study: NCT05186818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg)
Description: CK-3773274 tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match CK-3773274
Description: Placebo administered orally
Study: NCT04659031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: ABC008
Study: NCT06629961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abutment placement
Description: Placement of a subcrestal implant at more than 35 N and placement of a trans-epithelial abutment at 30 N

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ti-base placement
Description: Placement of a subcrestal implant at more than 35 N and placement of a Tibase placement at 30 N
Study: NCT04809805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2666605
Description: One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2666605
Description: One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
Study: NCT05715762

Intervention type: BEHAVIORAL
Intervention: prone postion
Description: ventilation at prone positioning

Intervention type: BEHAVIORAL
Intervention: prone postion
Description: ventilation at prone positioning

Intervention type: BEHAVIORAL
Intervention: prone postion
Description: ventilation at prone positioning

Intervention type: BEHAVIORAL
Intervention: prone postion
Description: ventilation at prone positioning

Intervention type: DRUG
Intervention: NO inhalation
Description: NO inhalation at 20 ppm

Intervention type: DRUG
Intervention: NO inhalation
Description: NO inhalation at 20 ppm
Study: NCT05046730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ileostomy Reversal using Self Forming Magnets (SFM)
Description: The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ileostomy Reversal using Self Forming Magnets (SFM)
Description: The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
Study: NCT05385978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APHD-012
Description: Distal jejunal-release dextrose beads (Aphaia technology, AT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APHD-012P
Description: Distal jejunal-release placebo beads
Study: NCT05734495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor, tablet taken orally.
Study: NCT06025643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS - Cervical stimulation group
Description: TENS will be applied bilaterally through self-adhesive electrodes in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS - Plus cervical stimulation group
Description: TENS will be applied bilaterally in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes, on the earlobe, on the wrists and ankles simultaneously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS - Renal stimulation group
Description: TENS will be applied through self-adhesive electrodes in the abdomen (anatomical region corresponding to the kidneys) and dorsal region at the level of the 10th thoracic vertebra.
Study: NCT05175664

Intervention type: OTHER
Intervention: Long-term study
Description: No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.

Intervention type: OTHER
Intervention: Long-term study
Description: No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.

Intervention type: OTHER
Intervention: Short-term study
Description: No intervention. Investigations: blood samples and pupillometry.

Intervention type: OTHER
Intervention: Cross-sectional study
Description: No intervention. Investigations: cognitive tests, pupillometry and actigraphy.

Intervention type: OTHER
Intervention: Cross-sectional study
Description: No intervention. Investigations: cognitive tests, pupillometry and actigraphy.

Intervention type: OTHER
Intervention: Cross-sectional study
Description: No intervention. Investigations: cognitive tests, pupillometry and actigraphy.

Intervention type: OTHER
Intervention: Cross-sectional study
Description: No intervention. Investigations: cognitive tests, pupillometry and actigraphy.

Intervention type: OTHER
Intervention: Cross-sectional study
Description: No intervention. Investigations: cognitive tests, pupillometry and actigraphy.

Intervention type: OTHER
Intervention: Cross-sectional study
Description: No intervention. Investigations: cognitive tests, pupillometry and actigraphy.
Study: NCT05259553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Peripheral blood sampling will be performed at different time points of the study, for a total volume of 20-40 mL:~* Sampling before MM treatment,~* Sampling during MM treatment (at 3 months post-initiation if no autograft or before autograft),~* Only for Patients treated with Apixaban or Eliquis®, 2 additional samplings during MM treatment for pharmacokinetics analysis.
Study: NCT06000722

Intervention type: OTHER
Intervention: eDelphi method
Description: This is a Delphi technique-based study using a purposive sample of convenience. Consensus development methods will be used to generate clinical guidelines, endorsed by key clinical groups, on the use of SGLT2i's in patients with diabetic foot ulcer disease, including acknowledgement of specific scenarios or patient characteristics that may influence these guidelines.
Study: NCT05754190

Intervention type: DEVICE
Intervention: SOMA pain manager smartphone application
Description: SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.

Intervention type: DEVICE
Intervention: SOMA pain manager smartphone application
Description: SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.

Intervention type: DEVICE
Intervention: SOMA pain manager smartphone application
Description: SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.
Study: NCT04367116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Spinal cord stimulation is a treatment that implants a electrode in posterior epidural space of patient's spinal canal to send mild electric current to stimulate conducting bundle of the posterior column of the spinal cord and posterior horn sensory neurons.
Study: NCT06524180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will be followed up as usual by face-to-face consultation with the doctors
Study: NCT05459753

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET
Description: Participants will receive an injection of 8 mCi \[18F\]FEOBV PET tracer and undergo a CT of the head.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dihydrotetrabenazine (DTBZ) PET
Description: Participants will receive an injection of 15 mCi \[11C\]DTBZ PET tracer and undergo a CT of the head.
Study: NCT05515224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-Cog Paradigm (5-Cog battery coupled with clinical decision tool)
Description: A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. If cognitive concerns are endorsed the 5-Cog battery will be conducted. The 5-Cog battery includes the Picture Memory Impairment Screen, Motoric Cognitive Risk Syndrome diagnosis, and Symbol Match. The simple, \<5-minute cognitive assessment will reliably identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. The results will be provided to primary care physicians.
Study: NCT05845580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red yeast rice extract initial therapy followed later on by statin therapy
Description: Patients will be offered red yeast rice extract to achieve a target LDL-cholesterol level of \<2.6 mmol/L, as recommended by the 2019 ESC/EAS guidelines. If a patient's LDL-cholesterol level remains above the target during follow-up, they will be informed that the natural alternative was ineffective, and they will be prescribed atorvastatin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Statin therapy
Description: Patients will be provided reassurance through a short, semi-structured discussion on the excellent safety profile of statins, similar to a typical interaction between a clinician and patient. They will then be prescribed atorvastatin.
Study: NCT05493332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC(FOLFOX)
Description: After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of chemotherapy drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 IVdrip from hour 0 to 2 on D1，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m2 IVdrip , from hour 0 to 2 on D1 to D2，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400mg/m2 , bolus at hour 3 ; and 600mg/m2 IVdrip over 46 hours on D1 to D2，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg IVdrip，D3, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 0.1g. P.O, BID, continuously
Study: NCT04835519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor T cell
Description: Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 5 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m\^2( body surface area) and cyclophosphamide 250 mg/m\^2( body surface area) for 3 days. Then this study will be using the Bayesian optimal interval phase I/II (Boin12) trial design. The protocol preset 2 dose levels: Dose 1 (DL-1) was 5×10\^5 (±20%) CAR T cells/kg, and dose 2 (DL-2) was 1×10\^6 (±20%) CAR T cells/kg. If the above dose cannot be met, subjects can still enter the study upon investigator consideration but require documentation of dosing. The lowest dose is 1×10\^5 CAR T cells/kg (±20%), and the highest dose is 1×10\^6 CAR T cells/kg (±20%). If the dose is out of the range mentioned above, entry into the trial will not be considered.
Study: NCT05959733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bridging Reconstruction using BioBrace
Description: Patients in the reconstruction group will undergo maximal repair with interposition bridging using BioBrace. This technique will follow a previously described technique by the principal investigator with differences allocated to the graft, it's preparation and insertion. The bursa will be debrided, and rotator cuff edged will be shaved down to stable tissue. BioBrace is bioinductive scaffold composed of highly porous type I collagen and bio-resorbable poly (L-lactide) (PLLA) microfilaments, and will be used as the graft in this trial.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair
Description: Patients in the maximal repair group will undergo a SCOI-row rotator cuff repair with adequate tension as described previously, with recreation of the rotator cable. Briefly, the SCOI-row rotator cuff repair uses one triple loaded suture anchor for each 1.2cm of torn tendon. This technique has been completed in a previous randomized controlled trial.
Study: NCT05347277

Intervention type: DIAGNOSTIC_TEST
Intervention: Kappa Free Light Chain (K-FLC)
Description: A biochemical test measured on CSF sample via nephelometry on Beckman Immage-800 analyzer using kits from Freelite, The Binding Site, according to the manufacturer's instructions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Kappa Free Light Chain (K-FLC)
Description: A biochemical test measured on CSF sample via nephelometry on Beckman Immage-800 analyzer using kits from Freelite, The Binding Site, according to the manufacturer's instructions.
Study: NCT04659031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: ABC008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: ABC008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: ABC008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: ABC008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: ABC008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: ABC008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: ABC008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: ABC008
Study: NCT05642000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SASEA HUB
Description: SASEA HUB website, an intervention tool to increase COVID-19 testing
Study: NCT06306846

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT+immunochemotherpy
Description: SBRT radiotherapy，followed with PD-1 monoclonal antibody and TP chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunochemotherapy
Description: PD-1 monoclonal antibody and TP chemotheapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab+immunochemotharpy
Description: PD-1 monoclonal antibody and TP chemotheapy combined with cetuximab
Study: NCT06457607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LinearZ
Description: High Intensity Focues Ultrasound
Study: NCT06063330

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RQ-001
Description: Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator. Drug Product RQ-001 has been developed with an Aptar Bidose liquid nasal spray unit device (BDSI V3) capable of intranasally delivering a 200 uL total volume of drug product (specifically, 100 uL per nare, which delivers a 200 uL of total volume). The combination product comprises the drug constituent (RQ-01) and the assembly of commercially available, off-the-shelf device components.~Study staff will be responsible for assembling the drug product RQ-001 and subjects will self-administer under the supervision of study staff in the clinic.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RQ-001
Description: Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator. Drug Product RQ-001 has been developed with an Aptar Bidose liquid nasal spray unit device (BDSI V3) capable of intranasally delivering a 200 uL total volume of drug product (specifically, 100 uL per nare, which delivers a 200 uL of total volume). The combination product comprises the drug constituent (RQ-01) and the assembly of commercially available, off-the-shelf device components.~Study staff will be responsible for assembling the drug product RQ-001 and subjects will self-administer under the supervision of study staff in the clinic.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be manufactured just as RQ-01 drug substance, with the active ingredient addition step omitted. Placebo will appear similar to RQ-01 drug substance as a clear to hazy, colorless to yellowish liquid. Matching placebo will be administered the same way as RQ-01
Study: NCT05668091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir
Description: Two 150 mg tablets taken by mouth every 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: One 100 mg capsule taken by mouth every 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ritonavir
Description: One 100 mg capsule taken by mouth every 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours.